Un cas de sécurité de déploiement pour la diagnostic du cancer de la prostate assisté par l'IA.
PMID : 40345136 ·
Y, a, n, , J, i, a, ;, , C, l, a, r, e, , V, e, r, r, i, l, l, ;, , K, i, e, r, o, n, , W, h, i, t, e, ;, , M, o, n, i, c, a, , D, o, l, t, o, n, ;, , M, a, r, g, a, r, e, t, , H, o, r, t, o, n, ;, , M, u, f, a, d, d, a, l, , J, a, f, f, e, r, j, i, ;, , I, b, r, a, h, i, m, , H, a, b, l, i
Publicité
Résumé
Deep learning (DL) has the potential to deliver significant clinical benefits. In recent years, an increasing number of DL-based systems have been approved by the relevant regulators, e.g. FDA. Although obtaining regulatory approvals is a prerequisite to deploy such systems for real world use, it may not be sufficient. Regulatory approvals give confidence in the development process for such systems, but new hazardous events can arise depending on how the systems have been deployed in the intende
Publicité
Source officielle
Voir sur PubMed →Données issues de PubMed / NCBI. Pour le texte intégral et les informations les plus récentes, consultez toujours la notice officielle.